Merck's Keytruda, passing Opdivo, bags double head and neck cancer OK

Keytruda
Merck's Keytruda picked up both monotherapy and combo approvals for Keytruda in first-line head and neck cancer. (Keytruda)

Tuesday was a twofer for Merck & Co., which notched two new FDA approvals for blockbuster Keytruda in previously untreated head and neck cancer patients.

Regulators green-lighted the immuno-oncology star as monotherapy in patients whose tumors bear the biomarker PD-L1 and in combination with a commonly used chemo regimen in patients regardless of PD-L1 status.

RELATED: Merck's Keytruda looks to zoom past Opdivo with fast head and neck cancer review

The regulatory wins follow a quick review from the agency, which bestowed its priority designation on Keytruda back in February.

FDA staffers based the speed-up on data showing that that, when facing off against a standard-of-care regimen commonly referred to by the name “Extreme,” Keytruda could lower the risk of death by 22% in PD-L1 positive patients. And when paired with chemo, Keytruda slashed the risk of death by 23% regardless of patients’ PD-L1 status.

With the OKs, Keytruda becomes the first in its class of PD-1/PD-L1 drugs into the first-line head and neck cancer market. The go-ahead unlocks potential use in more than 65,000 patients diagnosed each year in the U.S., Merck said.

It also puts Keytruda ahead of archrival Opdivo from Bristol-Myers Squibb, which is cleared only for patients who have already failed on chemo—meaning those who start out on Keytruda instead of chemo won’t be eligible for Opdivo treatment later.

RELATED: Merck heaps early pressure on Bristol-Myers' Opdivo with Keytruda's kidney cancer debut

And the last thing Bristol-Myers needs is to trail Keytruda in another therapy area. It’s already ceded the lead in lung cancer, immuno-oncology’s most lucrative market—and Keytruda has run away with it. And in kidney cancer, an area that’s been historically important to Opdivo sales, Merck recently arrived on the scene with a competing combo approval.

Suggested Articles

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectables drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.

An $8 billion jury verdict against Johnson & Johnson raised eyebrows back in October, but the judge has now slashed damages to just $6.8 million.